ERBB2 and breast cancer: To explore the key cellular process that contributes to increased CTC rates and the malignant progression of TNBC, we compared the expression profiles of TNBC, HR+, and HER2+ subtype tumor tissues in TCGA breast cancer dataset (Figure 1C).